STOCK TITAN

PTC Therapeutics Inc - PTCT STOCK NEWS

Welcome to our dedicated news page for PTC Therapeutics (Ticker: PTCT), a resource for investors and traders seeking the latest updates and insights on PTC Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect PTC Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of PTC Therapeutics's position in the market.

Rhea-AI Summary
Results from the APHENITY trial in PKU and long-term extension study to be presented at SSIEM Annual Symposium 2023. Sepiapterin treated patients maintain mean blood Phe control while increasing protein intake. Symposium to discuss latest trial results and sepiapterin features.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.76%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.99%
Tags
-
Rhea-AI Summary
PTC Therapeutics announces positive opinion for the extension of Evrysdi marketing authorization to include infants under two months of age in the EU. The decision is pending final approval from the European Commission. The CHMP opinion is based on the RAINBOWFISH interim analysis, showing positive results in infants treated with Evrysdi.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.95%
Tags
none
Rhea-AI Summary
PTC Therapeutics, Inc. will host a webcast conference call on August 3 to report its second quarter 2023 financial results and provide an update on the company's business and outlook. The call will be accessible via phone or webcast. A replay of the call will be available on the company's website for 30 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.17%
Tags
conferences earnings
-
Rhea-AI Summary
PTC Therapeutics, Inc. (NASDAQ: PTCT) announced that Allan Jacobson, Ph.D., co-founder and Board member, received the 2023 Gruber Genetics Prize for his work in nonsense-mediated mRNA decay. This prestigious award recognizes Dr. Jacobson's groundbreaking research in rare diseases and the development of Translarna, a key treatment success for PTC.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.17%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.29%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.17%
Tags
management
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.12%
Tags
none
-
Rhea-AI Summary
PTC Therapeutics' MIT-E trial of vatiquinone for the treatment of mitochondrial disease associated seizures (MDAS) failed to achieve its primary endpoint of reducing observable motor seizures. However, the study showed evidence of treatment effect in reducing seizure frequency in the overall study population and in children with Leigh syndrome. PTC Therapeutics plans to discuss the results of the MOVE-FA trial of vatiquinone for the treatment of Friedreich ataxia with regulatory authorities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.36%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.69%
Tags
PTC Therapeutics Inc

Nasdaq:PTCT

PTCT Rankings

PTCT Stock Data

2.02B
56.48M
2.79%
112.93%
13.39%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
South Plainfield

About PTCT

ptc is biopharmaceutical company focused on the discovery and development of orally-administered, proprietary small molecule drugs that target post-transcriptional control processes. while ptc’s discovery programs are directed at targets in multiple therapeutic areas, ptc is focusing particularly on the development and commercialization of treatments for orphan and ultra-orphan disorders. post-transcriptional control processes regulate the rate and timing of protein production and are essential to proper cellular function. ptc’s internally-discovered pipeline addresses multiple therapeutic areas, including neuromuscular disorders, oncology and infectious diseases. for more information on the company, please visit our website www.ptcbio.com.